DiagnoNET is a direct response to the need for streamlined processes to utilize molecular diagnostics in medical research and clinical routine. The company was founded in 2009 by Dr. Peter Amersdorfer, who has over 20 years of experience in biopharmaceutical and diagnostic research organizations.

 

Peter played an integral role in a broad spectrum of activities including preclinical drug discovery, biomarker validation, antibody engineering and strategic business development.  He has a proven track record in the evaluation and development of innovative products and services derived from breakthrough technology platforms including Phylos Inc. (now Adnexus, subsidiary of Bristol-Myers Squibb Company), Corvas International Inc. (acquired by Dendreon Inc.), Oridis-Biomed GmbH, Protagen AG and Lacerta Technologies GmbH (now Orthosera GmbH).

 

Peter’s accomplishments include patent applications, scientific publications and one antibody therapeutics program against Botulinum Neurotoxin Type A currently in clinical development arising from his Ph.D. work in the laboratory of Dr. James Marks, University of California San Francisco.

 

A detailed CV can be viewed at LinkedIn.

 

We accept assignments both as consultant or intermediary, and provide ancillary services including business development, project management and financing. Knowing the opportunities for European framework initiative and governmental financing tools, we structure on occasion special investment programs to bridge the unique know-how of clients from industry and academic competence centers for R&D programs.